NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce the price of its previously announced marketed public offering of units of the Company (the “Units” or the “Offered Securities”…


Previous articleTryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment
Next articleatai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer